Literature DB >> 33043165

Oncogenic and tumor-suppressive microRNAs in prostate cancer.

Morgan L Zenner1, Bethany Baumann1, Larisa Nonn1,2.   

Abstract

MicroRNAs are known to be dysregulated in prostate cancer. These small noncoding RNAs can function as biomarkers and are involved in the biology of prostate cancer. The canonical mechanism for microRNAs is post-transcription regulation of gene expression via binding to the 3' untranslated region of mRNAs, resulting in RNA degradation and/or translational repression. Thus, oncogenic microRNAs, also known as oncomiRs, often have high expression in prostate cancer and target the mRNAs of tumor suppressors. Conversely, tumor-suppressive microRNAs have reduced expression in cancer and typically target oncogenes. Some microRNAs function outside the classical mechanism and serve to stabilize their mRNA targets. Herein, we review contemporary studies that demonstrate oncogenic and tumor-suppressive activity of microRNAs in prostate cancer.

Entities:  

Keywords:  MicroRNAs; OncomiRs; Prostate cancer

Year:  2020        PMID: 33043165      PMCID: PMC7544188          DOI: 10.1016/j.coemr.2020.02.002

Source DB:  PubMed          Journal:  Curr Opin Endocr Metab Res        ISSN: 2451-9650


  75 in total

1.  C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.

Authors:  A Cannistraci; G Federici; A Addario; A L Di Pace; L Grassi; G Muto; D Collura; M Signore; L De Salvo; S Sentinelli; G Simone; M Costantini; S Nanni; A Farsetti; V Coppola; R De Maria; D Bonci
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

2.  MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway.

Authors:  Dawei Wang; Guoliang Lu; Yuan Shao; Da Xu
Journal:  Biomed Pharmacother       Date:  2018-03       Impact factor: 6.529

3.  MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer.

Authors:  Yongxiang Zhao; Mingyu Yan; Ye Yun; Jianguo Zhang; Ruimin Zhang; Yan Li; Xiangming Wu; Qiang Liu; Wei Miao; Haishan Jiang
Journal:  Oncol Rep       Date:  2017-03-13       Impact factor: 3.906

4.  Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation.

Authors:  Wenjun Ju; Atsushi Ogawa; Joerg Heyer; Dirk Nierhof; Liping Yu; Raju Kucherlapati; David A Shafritz; Erwin P Böttinger
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

5.  The miR-203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3β/β-CATENIN signal pathway.

Authors:  Xinxin Tian; Fangfang Tao; Baotong Zhang; Jin-Tang Dong; Zhiqian Zhang
Journal:  IUBMB Life       Date:  2018-02-01       Impact factor: 3.885

6.  miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer.

Authors:  Noushin Nabavi; Nur Ridzwan Nur Saidy; Erik Venalainen; Anne Haegert; Abhijit Parolia; Hui Xue; Yuwei Wang; Rebecca Wu; Xin Dong; Colin Collins; Francesco Crea; Yuzhuo Wang
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

7.  Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.

Authors:  Yubo Tang; Jincheng Pan; Shuai Huang; Xinsheng Peng; Xuenong Zou; Yongxiang Luo; Dong Ren; Xin Zhang; Ronggang Li; Peiheng He; Qingde Wa
Journal:  J Exp Clin Cancer Res       Date:  2018-07-18

8.  Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.

Authors:  Claire E Fletcher; Eric Sulpice; Stephanie Combe; Akifumi Shibakawa; Damien A Leach; Mark P Hamilton; Stelios L Chrysostomou; Adam Sharp; Jon Welti; Wei Yuan; Dafydd A Dart; Eleanor Knight; Jian Ning; Jeffrey C Francis; Evangelia E Kounatidou; Luke Gaughan; Amanda Swain; Shawn E Lupold; Johann S de Bono; Sean E McGuire; Xavier Gidrol; Charlotte L Bevan
Journal:  Oncogene       Date:  2019-05-01       Impact factor: 9.867

9.  MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.

Authors:  Baogang Sun; Yingying Fan; Aijun Yang; Lunan Liang; Jinghe Cao
Journal:  J Cell Mol Med       Date:  2019-07-12       Impact factor: 5.310

10.  The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways.

Authors:  Yang Yang; Changwei Ji; Suhan Guo; Xin Su; Xiaozhi Zhao; Shiwei Zhang; Guangxiang Liu; Xuefeng Qiu; Qing Zhang; Hongqian Guo; Huimei Chen
Journal:  Oncotarget       Date:  2017-08-24
View more
  2 in total

Review 1.  From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.

Authors:  Ekaterina Nevedomskaya; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

Review 2.  Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.

Authors:  Katalin Balázs; Lilla Antal; Géza Sáfrány; Katalin Lumniczky
Journal:  J Pers Med       Date:  2021-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.